scholarly journals Intraocular Pressure–Lowering Effects and Safety of Topical Administration of a Selective ROCK Inhibitor, SNJ-1656, in Healthy Volunteers

2008 ◽  
Vol 126 (3) ◽  
pp. 309 ◽  
Author(s):  
Hidenobu Tanihara
Keyword(s):  
Intraocular Pressure ◽  
Healthy Volunteers ◽  
Topical Administration ◽  
Rock Inhibitor ◽  
Pressure Lowering

scholarly journals Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and Monkeys

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Yoshio Kaneko ◽  
Masayuki Ohta ◽  
Tomoyuki Isobe ◽  
Yuto Nakamura ◽  
Ken Mizuno
Keyword(s):  
Intraocular Pressure ◽  
Fixed Combination ◽  
Coiled Coil ◽  
Topical Administration ◽  
Therapeutic Agents ◽  
Rock Inhibitor ◽  
Uveoscleral Outflow ◽  
Combined Administration ◽  
Pressure Lowering ◽  
Antiglaucoma Agents

Ripasudil hydrochloride hydrate (K-115), a specific Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor, is developed for the treatment of glaucoma and ocular hypertension. Topical administration of ripasudil decreases intraocular pressure (IOP) by increasing conventional outflow through the trabeculae to Schlemm’s canal, which is different from existing agents that suppress aqueous humor production or promote uveoscleral outflow. In this study, we demonstrated that ripasudil significantly lowered IOP in combined regimens with other glaucoma therapeutic agents in rabbits and monkeys. Ripasudil showed additional effects on maximum IOP lowering or prolonged the duration of IOP-lowering effects with combined administration of timolol, nipradilol, brimonidine, brinzolamide, latanoprost, latanoprost/timolol fixed combination, and dorzolamide/timolol fixed combination. These results indicate that facilitation of conventional outflow by ripasudil provides additive IOP-lowering effect with other classes of antiglaucoma agents. Ripasudil is expected to have substantial utility in combined regimens with existing agents for glaucoma treatment.

The effect of Benzalkonium chloride on the intraocular pressure lowering efficacy of a local ROCK-inhibitor (AMA0076)

2012 ◽  
Vol 90 ◽  
pp. 0-0
Author(s):  
K HOLLANDERS ◽  
D SIJNAVE ◽  
T VAN BERGEN ◽  
S VAN DE VELDE ◽  
L MOONS ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Benzalkonium Chloride ◽  
Rock Inhibitor ◽  
Pressure Lowering

scholarly journals Effect of Intraoperative Use of Topical Mitomycin C on Intraocular Pressure in Patients with Pterygium Excision

1970 ◽  
Vol 12 (3) ◽  
pp. 144-148
Author(s):  
Pir Salim Mahar ◽  
Nabeel Manzar ◽  
Khabir Ahmed
Keyword(s):  
Intraocular Pressure ◽  
Mitomycin C ◽  
Ciliary Body ◽  
Case Series ◽  
Topical Administration ◽  
Significant Decline ◽  
Paired Student ◽  
Pressure Lowering ◽  
Pterygium Excision

Aim: To determine the effect of intraoperative adjunctive topical mitomycin C on intraocular pressure in patients undergoing pterygium excision.Methods: This was a descriptive interventional case series of 102 patients (118 eyes) with different grades of pterygium treated from 1995 to 2008. All patients underwent pterygium excision with intraoperative mitomycin C 0.2 mg/mL administered for 1 to 5 minutes. Changes in intraocular pressure were recorded on days 1 and 7, and at 3 months. Data were analysed using proportion, group means, standard deviations, analysis of variance, and paired Student t test.Results: There was no significant decline in intraocular pressure throughout the follow-up period (p = 0.435, Student t test). At 3 months postoperatively, 109 eyes (92.4%) had no changes in intraocular pressure >5 mm Hg, of whom 78 (72%) experienced minimal changes that were not statistically significant.Conclusions: Intraoperative topical administration of mitomycin C has a minimal effect on lowering intraocular pressure in patients with pterygium. These results do not support the trans-scleral effect of mitomycin C on the ciliary body as an intraocular pressure–lowering mechanism in glaucoma filtering surgery.

Early results of micropulse transscleral cyclophotocoagulation for the treatment of glaucoma

2019 ◽  
Vol 30 (4) ◽  
pp. 700-705 ◽  
Author(s):  
Alexander T Nguyen ◽  
Jessica Maslin ◽  
Robert J Noecker
Keyword(s):  
Intraocular Pressure ◽  
Continuous Wave ◽  
Open Angle Glaucoma ◽  
Case Series ◽  
Angle Closure ◽  
Secondary Outcome ◽  
Early Results ◽  
Pressure Lowering ◽  
Transscleral Cyclophotocoagulation ◽  
The Mean

Purpose: To describe our clinical experience with the efficacy and safety of micropulse transscleral cyclophotocoagulation as a treatment for glaucoma. Methods: In this retrospective case series, we reviewed the charts of 95 consecutive patients with various glaucoma subtypes who underwent micropulse transscleral cyclophotocoagulation. Patients were offered micropulse transscleral cyclophotocoagulation if they had perimetric glaucoma refractory to intraocular pressure–lowering topical medications and who were poor candidates for traditional filtering surgery. Eligible patients were treated with the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2.0–2.5 W for a duration of 90 s per hemisphere at a 31.3% duty cycle. If a retreatment was needed, the power was increased to up to 3.0 W with other parameters remaining the same. Patients were considered successfully treated if their intraocular pressure was lowered by at least 20% compared to their baseline. The main outcome measure was post-operative intraocular pressure; secondary outcome measures included the number of adverse events and complications that occurred with treatment. Results: The glaucoma subtypes treated included primary open-angle glaucoma (n = 51), exfoliation glaucoma (n = 24), chronic angle-closure glaucoma (n = 15), and congenital/juvenile glaucoma (n = 5). The mean pre-operative intraocular pressure was 25.1 ± 5.3 mm Hg and the mean post-operative intraocular pressure at 12 months was 17.5 ± 5.1 mm Hg (p = 0.004). The mean number of intraocular pressure–lowering medications used preoperatively was 3.0 ± 1.1; the mean number of medications used at the 12-month post-operative visit was 1.4 ± 1.0 (p = 0.03). Success with one treatment was achieved in 73 (76.8%) of patients. With multiple treatments, all patients had significant intraocular pressure–lowering compared to baseline. The maximum number of treatments received by any single patient was 5. There were no instances of prolonged intraocular inflammation or long-term hypotony. Conclusion: Micropulse transscleral cyclophotocoagulation appears to be a safe and efficacious treatment for glaucoma. Given its improved safety profile compared to continuous-wave transscleral cyclophotocoagulation, it deserves consideration as a primary procedure.

scholarly journals Association between Rates of Retinal Nerve Fiber Layer Thinning after Intraocular Pressure–Lowering Procedures and Disc Hemorrhage

2020 ◽  
Vol 3 (1) ◽  
pp. 7-13 ◽  
Author(s):  
Huiyuan Hou ◽  
Sasan Moghimi ◽  
Linda M. Zangwill ◽  
James A. Proudfoot ◽  
Tadamichi Akagi ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Nerve Fiber ◽  
Retinal Nerve Fiber Layer ◽  
Fiber Layer ◽  
Disc Hemorrhage ◽  
Nerve Fiber Layer ◽  
Pressure Lowering ◽  
Retinal Nerve Fiber

scholarly journals Intraocular Pressure-Lowering Potential of Subthreshold Selective Laser Trabeculoplasty in Patients with Primary Open-Angle Glaucoma

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Hong Yang Zhang ◽  
Yong Jie Qin ◽  
Yang Fan Yang ◽  
Jian Gang Xu ◽  
Min Bin Yu
Keyword(s):  
Intraocular Pressure ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Initial Energy ◽  
The Other ◽  
Open Angle ◽  
Selective Laser Trabeculoplasty ◽  
Laser Trabeculoplasty ◽  
Pressure Lowering ◽  
Laser Flare

Purpose.To compare the efficacy of subthreshold and conventional selective laser trabeculoplasty (SLT) in lowering intraocular pressure (IOP) in the patients with primary open-angle glaucoma (POAG).Methods.Fifty-two eyes from fifty-two POAG patients were randomized into two groups, one group treated with subthreshold SLT using two-thirds of the conventional energy and the other one treated with the conventional energy. IOP was measured with the Goldmann tonometer and the anterior chamber inflammation was determined using laser flare meter.Results.The initial energy dosage used in subthreshold SLT group was significantly lower than the amount of the energy used in conventional SLT group (0.4±0.1 mJ versus0.6±0.1 mJ,P=0.030). The total energy dosage was also significantly lower in subthreshold SLT group compared to the other group (37.6±3.3 mJ versus51.8±5.7 mJ,P=0.036). However, the level of inflammation in aqueous humor, amount of reduction in IOP, and the success rate in controlling IOP was the same in both groups.Conclusion.The efficacy of subthreshold SLT group in reducing IOP in POAG patients is comparable to the efficacy of conventional SLT group.

Sign in / Sign up

Export Citation Format

Share Document